BMRN– BioMarin Pharmaceutical Inc evelops and commercializes pharmaceuticals for various diseases and medical conditions.
BMRN– BioMarin Pharmaceutical Inc
|Fundamentals||Previously closed at||89.65|
|Analysts opinion||BioMarin is a specialist in rare-disease specialist. The controversial drug Kyndrisa, which intended to treat Duchenne muscular dystrophy was rejected by the Committee for Medical Products for Human Use (CHMP). Analyst confidence meter, a proprietary algorithm of Stockal gives 89% buy based on analyst ratings.|
|Sentiments||The sentiment index is 50% positive according to Stockal proprietary algorithm.|
|NA Media Pulse||The stock has 64% higher social media chatter than usual.|